Literature DB >> 7658698

Nitric oxide modulation of the growth and differentiation of freshly isolated acute non-lymphocytic leukemia cells.

P J Shami1, J O Moore, J P Gockerman, J W Hathorn, M A Misukonis, J B Weinberg.   

Abstract

Freshly isolated acute non-lymphocytic leukemia (ANLL) cells were treated with the nitric oxide (NO)-liberating compounds sodium nitroprusside or S-nitrosoacetyl penicillamine and analyzed for viability, growth, and differentiation at 3-5 days. NO decreased the viability and the growth of freshly isolated ANLL cells in vitro. NO treatment significantly increased expression of CD14 in blast cells from patients with M5 ANLL, and increased at least one differentiation parameter in M4 or M5 cells. It had little or no effect on parameters of differentiation in other ANLL cells. We conclude that in vitro culture with NO decreases the growth and viability of most freshly isolated ANLL cells. NO also induces the differentiation of ANLL cells with a monocytic phenotype.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7658698     DOI: 10.1016/0145-2126(95)00013-e

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  11 in total

1.  JS-K has potent anti-angiogenic activity in vitro and inhibits tumour angiogenesis in a multiple myeloma model in vivo.

Authors:  Tanyel Kiziltepe; Kenneth C Anderson; Jeffery L Kutok; Lee Jia; Kenneth M Boucher; Joseph E Saavedra; Larry K Keefer; Paul J Shami
Journal:  J Pharm Pharmacol       Date:  2010-01       Impact factor: 3.765

2.  An isoelectronic NO dioxygenase reaction using a nonheme iron(III)-peroxo complex and nitrosonium ion.

Authors:  Atsutoshi Yokoyama; Jung Eun Han; Kenneth D Karlin; Wonwoo Nam
Journal:  Chem Commun (Camb)       Date:  2014-02-18       Impact factor: 6.222

3.  JS-K, a nitric oxide-releasing prodrug, modulates ß-catenin/TCF signaling in leukemic Jurkat cells: evidence of an S-nitrosylated mechanism.

Authors:  Niharika Nath; Mitali Chattopadhyay; Liliya Pospishil; Lucyna Z Cieciura; Satindra Goswami; Ravinder Kodela; Joseph E Saavedra; Larry K Keefer; Khosrow Kashfi
Journal:  Biochem Pharmacol       Date:  2010-08-24       Impact factor: 5.858

Review 4.  An epigenetic perspective on the free radical theory of development.

Authors:  Michael J Hitchler; Frederick E Domann
Journal:  Free Radic Biol Med       Date:  2007-07-10       Impact factor: 7.376

5.  Hydroxyurea nitrosylates and activates soluble guanylyl cyclase in human erythroid cells.

Authors:  Vladan P Cokic; Silvana A Andric; Stanko S Stojilkovic; Constance T Noguchi; Alan N Schechter
Journal:  Blood       Date:  2007-11-09       Impact factor: 22.113

6.  Aryl bis(diazeniumdiolates): potent inducers of S-glutathionylation of cellular proteins and their in vitro antiproliferative activities.

Authors:  Daniela Andrei; Anna E Maciag; Harinath Chakrapani; Michael L Citro; Larry K Keefer; Joseph E Saavedra
Journal:  J Med Chem       Date:  2008-12-25       Impact factor: 7.446

7.  Gene expression profiling for nitric oxide prodrug JS-K to kill HL-60 myeloid leukemia cells.

Authors:  Jie Liu; Swati Malavya; Xueqian Wang; Joseph E Saavedra; Larry K Keefer; Erik Tokar; Wei Qu; Michael P Waalkes; Paul J Shami
Journal:  Genomics       Date:  2009-04-05       Impact factor: 5.736

8.  Synthesis, mechanistic studies, and anti-proliferative activity of glutathione/glutathione S-transferase-activated nitric oxide prodrugs.

Authors:  Harinath Chakrapani; Ravi C Kalathur; Anna E Maciag; Michael L Citro; Xinhua Ji; Larry K Keefer; Joseph E Saavedra
Journal:  Bioorg Med Chem       Date:  2008-09-30       Impact factor: 3.641

9.  Nitric Oxide-Releasing Hybrid Drugs Target Cellular Processes Through S-Nitrosylation.

Authors:  Khosrow Kashfi
Journal:  For Immunopathol Dis Therap       Date:  2012

10.  JS-K, an arylating nitric oxide (NO) donor, has synergistic anti-leukemic activity with cytarabine (ARA-C).

Authors:  Paul J Shami; Anna E Maciag; Jordan K Eddington; Vidya Udupi; Ken M Kosak; Joseph E Saavedra; Larry K Keefer
Journal:  Leuk Res       Date:  2009-02-03       Impact factor: 3.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.